MedTrace Logo

Bioequivalence Study of Methacholine for Inhalation (pharmacodynamics)

NCT06725641 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-12-10

No results posted yet for this study

Summary

This trial was divided into two parts. This is the scecond part. The second part is the pharmacodynamic equivalence study of patients, which is a single-dose, randomized, open, two-cycle, two-sequence crossover design, and plans to enroll 40 subjects.

Conditions

Interventions

DRUG

Test preparation：Methylcholine chloroacetate for inhalation

Cholinergic agonists

DRUG

Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）

Cholinergic agonists

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    collaborator INDUSTRY

  • China-Japan Friendship Hospital

    lead OTHER

Principal Investigators

  • Ting Yang, Doctor · China-Japan Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-24
Primary Completion
2024-10-22
Completion
2024-10-26

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06725641 on ClinicalTrials.gov